Angioplasty versus surgery in patients with critical lower limb ischemia

Original title: Comparative effectiveness of endovascular andsurgical revascularization for patients with peripheralartery disease and critical limb ischemia: Systematicreview of revascularization in critical limb ischemia. Reference: W Schuyler Jones, et al. (Am Heart J 2014; 167:167:489-498.e7)

Lower limbs critical ischemia is the most severe condition of PAD. The morbidity, mortality and costs related thereto are well documented; however, the method of choice to prevent amputation, death and preserve functional capacity is not yet defined. 

This paper reviewed the relevant studies published from 1995 to 2012, in which endovascular technique was compared with surgery regarding death, cardiovascular events, amputation, quality of life, patency of the case treated and reintervention. Both techniques in 23 works were compared totalling 12,779 patients with critical lower limb ischemia. One of the studies was randomized, and 22 were observational. The average age of the patients ranged between 61 and 83 years, the number of patients evaluated ranged from 73 to 4,929, and the length of study was 30 days to 60 months. The quality of the studies evaluated was also a variable.

In terms of all-cause mortality, no significant superiority of the endovascular procedure at 6 months was found, but this disappeared after two years, being the same in both procedures. No difference was found between the procedures in assessing long-term amputation. Nine studies assessed vessel patency, being higher in the endovascular procedure. One study evaluated the time to healing chronic wounds, resulting this lower in the surgical procedure. The research also assessed other variables such as age, anatomical factors, tissue loss and technique used, with varying results without statistical significance. None of the studies considered subgroups by sex, race, smoking or the presence of renal insufficiency.

Conclusion

The conclusion reached in the present meta-analysis is that the evidence available at the time for the treatment of critical lower limb ischemia is limited since it is based on few studies, most of them non-randomized, not superiority lies between angioplasty and surgery.

Editorial comment

The only important randomized study is the BASIL, which recruited patients more than 10 years ago to compare both techniques, however, in the endovascular branch, current technologies in terms of stents, balloons, etc., were not used. Even so, based on this information, in 2011 the existing guidelines were updated, indicating that both procedures were similar. Randomized studies are needed to compare both techniques using current technologies.

Courtesy of Alfonso Francisco Balaguer Quiroga MD
Interventional Cardiologist.
International Clinic. Lima, Peru.

Dr. Alfonso Francisco Balaguer Quiroga

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...